Expression Of Human Epidermal Growth Factor Receptor2and Its Association With The Clinicalpathological Features And Prognosis Of Pancreatic Ductal Adenocarcinoma

Purpose:This study aimed to detect the expressions of HER2in PDAC and normal pancreatic tissue and metastatic sites and to investigate its association with the clinicalpathological features and prognosis.Methods-.The expression of109PDAC,30metastasis in lymph node and27normal pancreatic tissue was determined by immunohistochemistry(IHC). Immuno-reactivity was classified according to the scale presented in the HercepTest Scoring Guidelines. The relationship of the HER2expression with patients survival was analyzed.ResultS:1.32cases (29.4%) had a score of0,39cases (35.8%) had a score of1+,28cases (25.7%) had a score of2+and10cases (9.2%) had a score of3+in the109PDCA without hematogenous metastases or peritoneal dissemination treated by macroscopically curative resection. Therefore, HER2overexpression (score2+or3+) was observed in38cases (34.9%). In27normal pancreatic tissues,24cases (88.9%) had a score of0and3cases (11.1%) had a score of1+. There was no case with score2+or3+. There was a higher score in PDCA than in normal pancreatic cancer (P<0.05).2. There were8case(26.7%) with HER2overexpression.The concordance in primary and paired metastatic sites was70%.3. In61cases of PDCA which has a negative cutting edge, patients with overexpression of HER2had a median survival time (MST) of16.23months while others had a MST of28.73months (P<0.05).Conclusion:The expression of HER2in PADC had a higher score than that in normal pancreatic tissue; for patients with PDAC which has undergone R0resection, those with HER2overexpression has a poorer prognosis than those without HER2overexpression.